As part of the agreement, Syntonix gains access to Zenobia’s technology and expertise in structural biology, crystallization and X-ray structure determination. Zenobia has completed three unique protein structures during the first five months of the agreement. The agreement includes research funding and milestone payments.
Zenobia has access to high-energy synchrotron sources for data collection through an agreement with Shamrock Biostructures, located near the Advanced Photon Source in Chicago, Illinois.
Vicki Nienaber, president and chief scientific officer of Zenobia, said: “Syntonix challenged us with a difficult program, and through close collaboration between our scientists, we are pleased to deliver results.”